Alnylam Pharmaceuticals ALNY Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's accounts receivable?
- Alnylam Pharmaceuticals (ALNY) reported accounts receivable of $912.74M in Q2 2026.
- How has Alnylam Pharmaceuticals's accounts receivable changed year-over-year?
- Alnylam Pharmaceuticals's accounts receivable increased by 60.9% year-over-year, from $567.11M to $912.74M.
- What is the long-term trend for Alnylam Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's accounts receivable has grown at a 50.0% compound annual growth rate (CAGR), from $102.41M to $777.57M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.